DDAVP in Uremia
Author(s) -
Vicente Vicente,
I Alberca,
Juan F. Macías Núñez,
A. López Borrasca
Publication year - 1984
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000183137
Subject(s) - medicine , uremia , nephrology , urology , endocrinology
Dr. V. Vicente, Departments of Hematology and Nephrology, University Hospital, Salamanca (Spain) Dear Sir, In recent years it has been shown that the intravenous injection of DDAVP (l-deamino-8-Darginine-vasopres-sin), a synthetic analogue of the antidiuretic hormone, provokes a rapid, marked, and transient increase of factor VΠI/von Willebrand factor (FVΠI/VWF) in normal subjects and patients with mild hemophilia A or von Wille-brand’s disease [1–3], Recently, Mannucci et al. [4] report that infusions of DDAVP shorten the prolonged bleeding time in patients with uremia. These authors suggest that this is dependent on the appearance in plasma of larger von Willebrand factor multimers than those present in the resting state. Uremia is commonly associated with wide variations in the levels of FVIΠ/VWF-related activities [5,6]. One of us has suggested that the response to DDAVP in subjects with elevated baseline concentrations of FVIΠ/VWF activities is accompanied by a decreased release from those storage pool(s) mobilized by DDAVP [7]. In the report of Mannucci et al. [4], levels of FVΠI/VWF activities were moderately elevated. We have evaluated the response of FVIΠ/VWF and bleeding time to DDAVP (0.3 μg/kg body weight) in 5 uremic patients (3 men and 2 women with an average age of 34 years, range 16–50) with chronic glomerulonephritis who were undergoing regular hemo-dialysis. These patients showed high levels of FVIΠ/VWF activities at the beginning of the study, which was begun 24 h after the end of dialysis (table I). The remaining clinical characteristics were similar to those described by Mannucci et al. [4]. Bleeding time and plasma collection were carried out immediately before DDAVP and again 1 h after the DDAVP infusion. Factor VIΠ/VWF activities were assayed as previously described [8]. Template bleeding time was assessed with the Simplate II device (General Diagnostic). Table I shows that the bleeding time was not Table I. Laboratory measurements before and after DDAVP in patients with uremia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom